Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
168
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply125
AP&T: Editors' Declarations of Interest103
Issue Information103
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification85
Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration82
CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy79
Issue Information74
71
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC70
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US67
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease67
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis65
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?64
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical St64
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease62
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep62
Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease62
Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis61
Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea60
No value of non‐selective beta‐blockers after TIPS‐insertion57
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment57
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients56
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome54
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study53
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply50
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease50
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply49
49
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?49
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies48
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation48
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study48
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis46
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis46
Issue Information44
44
Editorial: The future of managing drug induced liver injury43
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease43
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted42
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply42
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC42
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply42
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B42
0.11275410652161